FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787941699> ?p ?o ?g. }

• W2787941699 endingPage "485" @default.
• W2787941699 startingPage "474" @default.
• W2787941699 abstract "Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. Findings Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46–72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7–90·0) with the switch strategy and 89·8% (88·2–91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73–1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9–91·7) with anastrozole (124 events), 88·0% (85·8–89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3–4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3–4 adverse events occurred in less than 2% of patients in either group. Interpretation 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting. Funding Italian Drug Agency. Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aromatase inhibitors for 3 years (switch strategy). Randomisation was done by a computerised minimisation procedure stratified for oestrogen receptor, progesterone receptor, and HER2 status; previous chemotherapy; and pathological nodal status. Neither the patients nor the physicians were masked to treatment allocation. The primary endpoint was disease-free survival. The minimum cutoff to declare superiority of the upfront strategy over the switch strategy was assumed to be a 2% difference in disease-free survival at 5 years. Primary efficacy analyses were done by intention to treat; safety analyses included all patients for whom at least one safety case report form had been completed. Follow-up is ongoing. This trial is registered with the European Clinical Trials Database, number 2006-004018-42, and ClinicalTrials.gov, number NCT00541086. Between March 9, 2007, and July 31, 2012, 3697 patients were enrolled into the study. After a median follow-up of 60 months (IQR 46–72), 401 disease-free survival events were reported, including 211 (11%) of 1850 patients allocated to the switch strategy and 190 (10%) of 1847 patients allocated to upfront treatment. 5-year disease-free survival was 88·5% (95% CI 86·7–90·0) with the switch strategy and 89·8% (88·2–91·2) with upfront treatment (hazard ratio 0·89, 95% CI 0·73–1·08; p=0·23). 5-year disease-free survival was 90·0% (95% CI 87·9–91·7) with anastrozole (124 events), 88·0% (85·8–89·9) with exemestane (148 events), and 89·4% (87·3 to 91·1) with letrozole (129 events; p=0·24). No unexpected serious adverse reactions or treatment-related deaths occurred. Musculoskeletal side-effects were the most frequent grade 3–4 events, reported in 130 (7%) of 1761 patients who received the switch strategy and 128 (7%) of 1766 patients who received upfront treatment. Grade 1 musculoskeletal events were more frequent with the upfront schedule than with the switch schedule (924 [52%] of 1766 patients vs 745 [42%] of 1761 patients). All other grade 3–4 adverse events occurred in less than 2% of patients in either group. 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. None of the three aromatase inhibitors was superior to the others in terms of efficacy. Therefore, patient preference, tolerability, and financial constraints should be considered when deciding the optimal treatment approach in this setting." @default.
• W2787941699 created "2018-03-06" @default.
• W2787941699 creator A5000297270 @default.
• W2787941699 creator A5000473694 @default.
• W2787941699 creator A5000803284 @default.
• W2787941699 creator A5001293319 @default.
• W2787941699 creator A5002927531 @default.
• W2787941699 creator A5003029378 @default.
• W2787941699 creator A5003956612 @default.
• W2787941699 creator A5004001131 @default.
• W2787941699 creator A5004581470 @default.
• W2787941699 creator A5004747884 @default.
• W2787941699 creator A5005431384 @default.
• W2787941699 creator A5005549319 @default.
• W2787941699 creator A5005815956 @default.
• W2787941699 creator A5006355590 @default.
• W2787941699 creator A5006712720 @default.
• W2787941699 creator A5006857854 @default.
• W2787941699 creator A5007382846 @default.
• W2787941699 creator A5007488646 @default.
• W2787941699 creator A5008991955 @default.
• W2787941699 creator A5009104034 @default.
• W2787941699 creator A5009473646 @default.
• W2787941699 creator A5010499606 @default.
• W2787941699 creator A5010532660 @default.
• W2787941699 creator A5010553121 @default.
• W2787941699 creator A5010775220 @default.
• W2787941699 creator A5010972450 @default.
• W2787941699 creator A5011118091 @default.
• W2787941699 creator A5011953485 @default.
• W2787941699 creator A5012211936 @default.
• W2787941699 creator A5012371091 @default.
• W2787941699 creator A5012669847 @default.
• W2787941699 creator A5013062135 @default.
• W2787941699 creator A5013509413 @default.
• W2787941699 creator A5013748999 @default.
• W2787941699 creator A5014050798 @default.
• W2787941699 creator A5015074333 @default.
• W2787941699 creator A5015740152 @default.
• W2787941699 creator A5016655393 @default.
• W2787941699 creator A5016843734 @default.
• W2787941699 creator A5017440774 @default.
• W2787941699 creator A5017866134 @default.
• W2787941699 creator A5019053015 @default.
• W2787941699 creator A5020297889 @default.
• W2787941699 creator A5020324515 @default.
• W2787941699 creator A5020547991 @default.
• W2787941699 creator A5020635495 @default.
• W2787941699 creator A5020732852 @default.
• W2787941699 creator A5020740814 @default.
• W2787941699 creator A5020814680 @default.
• W2787941699 creator A5021397492 @default.
• W2787941699 creator A5021552763 @default.
• W2787941699 creator A5021919844 @default.
• W2787941699 creator A5022101551 @default.
• W2787941699 creator A5022124014 @default.
• W2787941699 creator A5022206145 @default.
• W2787941699 creator A5022680113 @default.
• W2787941699 creator A5023055484 @default.
• W2787941699 creator A5023104648 @default.
• W2787941699 creator A5023119083 @default.
• W2787941699 creator A5023921586 @default.
• W2787941699 creator A5024258015 @default.
• W2787941699 creator A5024709195 @default.
• W2787941699 creator A5025486771 @default.
• W2787941699 creator A5025522325 @default.
• W2787941699 creator A5025684262 @default.
• W2787941699 creator A5026022049 @default.
• W2787941699 creator A5026048739 @default.
• W2787941699 creator A5026237890 @default.
• W2787941699 creator A5026558326 @default.
• W2787941699 creator A5026665975 @default.
• W2787941699 creator A5027075905 @default.
• W2787941699 creator A5027273924 @default.
• W2787941699 creator A5027353243 @default.
• W2787941699 creator A5027811958 @default.
• W2787941699 creator A5028284107 @default.
• W2787941699 creator A5029239959 @default.
• W2787941699 creator A5029463545 @default.
• W2787941699 creator A5029630690 @default.
• W2787941699 creator A5029969206 @default.
• W2787941699 creator A5030013928 @default.
• W2787941699 creator A5030038670 @default.
• W2787941699 creator A5030758520 @default.
• W2787941699 creator A5030849745 @default.
• W2787941699 creator A5031115773 @default.
• W2787941699 creator A5031898133 @default.
• W2787941699 creator A5032067382 @default.
• W2787941699 creator A5032094088 @default.
• W2787941699 creator A5032747123 @default.
• W2787941699 creator A5032928173 @default.
• W2787941699 creator A5033619203 @default.
• W2787941699 creator A5033956695 @default.
• W2787941699 creator A5034109073 @default.
• W2787941699 creator A5034426439 @default.
• W2787941699 creator A5034676299 @default.
• W2787941699 creator A5034806738 @default.
• W2787941699 creator A5034879633 @default.

• next